Share on LinkedInShare on LinkedIn

ARTICLE · 03 MAY 2024

Drugmakers Exposed To Antitrust Probes If Patent Cache Added

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Contributor
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private...

View firm profile
Explore more from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Member Vanessa Yen and Special Counsel Evan Diamond spoke with Bloomberg Law on the US Patent and Trademark Office's proposed rule that would require parties ...

United StatesIntellectual Property

Member Vanessa Yen and Special Counsel Evan Diamond spoke with Bloomberg Law on the US Patent and Trademark Office's proposed rule that would require parties to file settlement agreements for patent challenges with the Patent Trial and Appeal Board — even when such agreements are entered before the PTAB institutes full proceedings.

Vanessa commented on the implications of the USPTO connecting this change to an Executive Order regarding antitrust law that President Biden signed in July 2021, saying, "By mentioning the EO, there's an implication they're making this change because there's something wrong with the settlements . . . But honestly, the opposite is true, because settlements can avoid burdening the PTAB, and can include clauses that allow generics or biosimilar entries years in advance of patent expiration."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from